1BOWEN D G,WALKER C M.The origin of quasispecies:cause orconsequence of chronic hepatitis C viral infection[J].J Hepatol,2005,42(3):408-417.
2KANG S M,CHOI S H,PARK C Y,et al.Monoclonal antibody recognizing N-terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication[J].J Viral Hepat,2008,15(4):305-313.
3BEAULIEU P L,TSANTRIZOS Y S.Inhibitors of the HCV NS5B polymerase:new hope for the treatment of hepatitis C infections[J].Curr Opin Investig Drugs,2004,5(8):838-850.
4SIMMONDS P,BUKH J,COMBET C,et al.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J].Hepatology,2005,42(4):962-973.
7SHEPARD C W,FINELLI L,ALTER M J.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567.
8SLAVENBURG S,VERDUYN LUNEL F M,HERMSEN J T,et al.Prevalence of hepatitis C in the general population in the Netherlands[J].Neth J Med,2008,66(1):13-17.
9POLIZZOTTO M N,WOOD E M,INGHAM H,et al.Reducing the risk of transfusion-transmissible viral infection through blood donor selection:the Australian experience 2000 through 2006[J].Transfusion,2008,48(1):55-63.
6Zeuzem S,Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response[J]. Curr Med Res Opin,2010,26(7) : 1733-43.
7RAMOS B, NDNEZ M,TBRO C,et al. Changes in the distri- bution of hepatitis C virus (HCV) genotype B over time in Spain according to HIV Serostatus: implications for HCV therapy in HCV/HIV confected patients[J]. J Infect, 2007,54 (2):173-179.
